Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
Pietro Iaffaldano(University of Bari Aldo Moro), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Franco Granella(University of Parma), Antonella Conte(Sapienza University of Rome), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), María Trojano(University of Bari Aldo Moro), Davide Maimone(Ospedale Garibaldi), Claudio Gasperini(Nini Hospital), Valentina Torri Clerici, Gıancarlo Comı(Casa di Cura Columbus), Maria Pia Amato(University of Florence), Marco Salvetti(Istituto Neurologico Mediterraneo), Giovanna De Luca(University of Udine), Francesca Caputo, Rocco Totaro(San Salvatore Hospital), Marco Rovaris(San Raffaele University of Rome), Damiano Paolicelli(University of Bari Aldo Moro), Matilde Inglese(New York University), Francesco Patti(University of Catania), Marco Capobianco(Ospedale San Luigi Gonzaga), Giuseppe Salemi, Patrizia Sola(Azienda Ospedaliero-Universitaria di Modena), Carlo Pozzilli(Sapienza University of Rome), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Eleonora Cocco(University of Cagliari), Giuseppe Lucisano(Center for Outcomes Research and Clinical Epidemiology), Vincenzo Brescia Morra(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Giorgia Teresa Maniscalco(Ospedale Antonio Cardarelli), Massimo Filippi(Vita-Salute San Raffaele University), Paolo Bellantonio(Vita-Salute San Raffaele University)
Cited by 119
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k